Clene Shares Outstanding 2018-2021 | CLNN

Clene shares outstanding from 2018 to 2021. Shares outstanding can be defined as the number of shares held by shareholders (including insiders) assuming conversion of all convertible debt, securities, warrants and options. This metric excludes the company's treasury shares.
Clene Annual Shares Outstanding
(Millions of Shares)
2020 18
2019 17
2018 1
2017
Clene Quarterly Shares Outstanding
(Millions of Shares)
2021-06-30 61
2021-03-31 61
2020-12-31 18
2020-09-30 2
2020-06-30 17
2020-03-31 17
2019-12-31 17
2019-09-30 2
2019-06-30 2
2019-03-31 2
2018-12-31 1
2018-09-30 2
2018-06-30 1
2018-03-31 1
2017-12-31
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.446B $0.000B
Clene Inc. is a clinical-stage biopharmaceutical company. It is focused on the development of unique therapeutics for neurodegenerative diseases. Clene Nanomedicine Inc., formerly known as Tottenham Acquisition I Limited, is based in SALT LAKE CITY.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $134.727B 8.97
Bio-Rad Laboratories (BIO.B) United States $23.483B 50.05
QIAGEN (QGEN) Netherlands $12.500B 21.17
Biohaven Pharmaceutical Holding (BHVN) United States $8.865B 0.00
Emergent Biosolutions (EBS) United States $2.891B 6.97
Arcus Biosciences (RCUS) United States $2.641B 0.00
Myovant Sciences (MYOV) United Kingdom $2.145B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.998B 0.00
Zymeworks (ZYME) Canada $1.380B 0.00
Ambrx Biopharma (AMAM) United States $0.521B 0.00
SQZ Biotechnologies (SQZ) United States $0.427B 0.00
Enzo Biochem (ENZ) United States $0.175B 51.71